Seihaito, a Kampo medicine, attenuates IL-13-induced mucus production and goblet cell metaplasia
Journal of Pharmacological Sciences · 2024
DOI: 10.1016/j.jphs.2024.02.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacological Sciences, 2024. Verfasst von Tomoki Sekiya und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Applied Pharmacology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba, 278-8510, Japan. Hauptthemen laut MEDLINE: Goblet Cells, Interleukin-13, Mucin 5AC, Medicine, Kampo. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Government of Japan Ministry of Education Culture Sports Science and Technology.
Abstract (Originalsprache)
Goblet cell hyperplasia and increased mucus production are features of airway diseases, including asthma, and excess airway mucus often worsens these conditions. Even steroids are not uniformly effective in mucus production in severe asthma, and new therapeutic options are needed. Seihaito is a Japanese traditional medicine that is used clinically as an antitussive and expectorant. In the present study, we examined the effect of Seihaito on goblet cell differentiation and mucus production. In in vitro studies, using air-liquid interface culture of guinea-pig tracheal epithelial cells, Seihaito inhibited IL-13-induced proliferation of goblet cells and MUC5AC, a major component of mucus production. Seihaito suppressed goblet cell-specific gene expression, without changing ciliary cell-specific genes, suggesting that it inhibits goblet cell differentiation. In addition, Seihaito suppressed MUC5AC expression in cells transfected with SPDEF, a transcription factor activated by IL-13. Furthermore, Seihaito attenuated in vivo goblet cell proliferation and MUC5AC mRNA expression in IL-13-treated mouse lungs. Collectively, these findings demonstrated that Seihaito has an inhibitory effect on goblet cell differentiation and mucus production, which is at least partly due to the inhibition of SPDEF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Applied Pharmacology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba, 278-8510, Japan.
- Laboratory of Applied Pharmacology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba, 278-8510, Japan. Electronic address: isohama@rs.tus.ac.jp.
Förderung
- Government of Japan Ministry of Education Culture Sports Science and Technology
Zitieren
APA
Sekiya, T., Murakami, K., & Isohama, Y. (2024). Seihaito, a Kampo medicine, attenuates IL-13-induced mucus production and goblet cell metaplasia. Journal of Pharmacological Sciences. https://doi.org/10.1016/j.jphs.2024.02.008
Vancouver
Sekiya T, Murakami K, Isohama Y. Seihaito, a Kampo medicine, attenuates IL-13-induced mucus production and goblet cell metaplasia. Journal of Pharmacological Sciences. 2024. doi:10.1016/j.jphs.2024.02.008
BibTeX
@article{Sekiya2024,
author = {Sekiya, Tomoki and Murakami, Kazuhito and Isohama, Yoichiro},
title = {Seihaito, a Kampo medicine, attenuates IL-13-induced mucus production and goblet cell metaplasia},
journal = {Journal of Pharmacological Sciences},
year = {2024},
doi = {10.1016/j.jphs.2024.02.008}
}
EUVIMED